Business Wire

Kinimmune publishes results from a Phase I “Window of Opportunity” trial in patients with solid tumors

ST. LOUIS--(BUSINESS WIRE)--Kinimmune, a clinical-stage biopharmaceutical company focused on the discovery and development of localized immunotherapies, announced the publication of clinical results ...
Business Wire

Akamis Bio Announces Publication Detailing Initial Proof of Mechanism for NG-350A, an IV-Dosed Tumor Gene Therapy Delivering a CD40 Agonist Payload

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, ...
Morningstar

Williams Cancer Institute Presents Data on Combined Pulsed Electrical Field Ablation and Intratumoral Immunotherapy at SITC 2025

BEVERLY HILLS, Calif., Nov. 10, 2025 /PRNewswire/ -- Williams Cancer Institute ("WCI"), a leading center pioneering the use of intratumoral immunotherapy for late-stage cancer patients, announced that ...
Nasdaq

Intensity Therapeutics, Inc.'s Phase 3 INVINCIBLE-3 Sarcoma Study Selected for Presentation at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

SHELTON, Conn., May 29, 2025 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and ...
Morningstar

Zetagen Therapeutics to Present Preliminary Results from Phase 2 Clinical Trial Targeting Metastatic Breast Cancer to Bone at the 2025 San Antonio Breast Cancer Symposium

Complete Response in all treated lesions: Patients completing the study showed CR via the MD Anderson Criteria and RECIST v1.1 with no active tumor detected on MRI First-of-its-kind single ...